Buy Rating Affirmed for Precision BioSciences on Strong Pipeline and Market Potential
Express News | Precision BioSciences Announces Grant of Inducement Awards Under Nasdaq Listing Rule 5635(C)(4)
Express News | HC Wainwright & Co. Reiterates Buy on Precision BioSciences, Maintains $60 Price Target
Precision BioSciences Analyst Ratings
Date Upside/Downside Analyst Firm Price Target Change Rating Change Previous / Current Rating 05/16/2024 395.87% HC Wainwright & Co. → $60 Reiterates Buy → Buy 04/30/2024 57.02% Guggenheim → $19 Initi
Analysts Offer Insights on Healthcare Companies: Precision BioSciences (DTIL) and Adicet Bio (ACET)
Maintaining Hold on Precision BioSciences Pending Clinical Data and Strategic Reassessments
Buy Rating Affirmed for Precision BioSciences on Advancing Gene Editing Pipeline and Strong Financials
Quarterly Results Takes Precision BioSciences Higher
Precision BioSciences Reports Profit From Cont. Ops. In Q1
Precision BioSciences | 10-Q: Quarterly report
Express News | Precision BioSciences Inc - Expected Runway Into H2 2026
Precision BioSciences Q1 EPS $1.70 Beats $(1.91) Estimate, Sales $17.58M Beat $6.02M Estimate
Precision BioSciences (NASDAQ:DTIL) reported quarterly earnings of $1.70 per share which beat the analyst consensus estimate of $(1.91) by 189.01 percent. This is a 124.64 percent increase over losses
Earnings Flash (DTIL) PRECISION BIOSCIENCES Reports Q1 Revenue $17.6M, Vs. Street Est of $6.02M
07:02 AM EDT, 05/13/2024 (MT Newswires) -- Earnings Flash (DTIL) PRECISION BIOSCIENCES Reports Q1 Revenue $17.6M, vs. Street Est of $6.02M
Express News | Precision BioSciences Reports First Quarter 2024 Financial Results and Provides Business Update
Precision Biosciences 1Q Rev $17.6M >DTIL
Precision Biosciences 1Q Rev $17.6M >DTIL
Stocks Poised for Lower Open
Stocks are poised to open lower in New York on Monday as investors await a key inflation reading later in the week and ahead of earnings reports from major retailers.
Express News | Precision BioSciences Announces Common Stock Purchase By Members Of Management, Including CEO, For $300,000 In Private Placement
Precision BioSciences Announces Common Stock Purchase by Members of Management for $300,000 in A...
Express News | Precision BioSciences Announces Common Stock Purchase by Members of Management for $300,000 in a Private Placement
Precision BioSciences to Report First Quarter Results on May 13, 2024
Precision BioSciences, Inc. (NASDAQ:DTIL), an advanced gene editing company utilizing its novel proprietary ARCUS platform to develop in vivo gene editing therapies for sophisticated gene edits, including gene